The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
Verywell Health on MSN4h
Spravato Nasal Spray Can Now Be Used Alone for Treatment-Resistant DepressionPeople with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...
Boing Boing on MSN4d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback